Braun Stacey Associates Inc. Makes New $9.69 Million Investment in Encompass Health Co. (NYSE:EHC)

Braun Stacey Associates Inc. acquired a new stake in Encompass Health Co. (NYSE:EHC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 104,907 shares of the company’s stock, valued at approximately $9,688,000. Braun Stacey Associates Inc. owned about 0.10% of Encompass Health at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EHC. TD Private Client Wealth LLC raised its stake in shares of Encompass Health by 2,870.0% during the 3rd quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock valued at $709,000 after buying an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in Encompass Health by 532.4% in the third quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock valued at $4,860,000 after acquiring an additional 42,338 shares during the period. Pathstone Holdings LLC grew its stake in shares of Encompass Health by 54.5% during the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock worth $2,032,000 after purchasing an additional 7,412 shares during the period. Meeder Asset Management Inc. grew its position in Encompass Health by 43.8% during the third quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company’s stock valued at $6,417,000 after buying an additional 20,242 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after purchasing an additional 20,547 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Price Performance

Encompass Health stock opened at $100.91 on Tuesday. The company has a 50-day moving average price of $95.95 and a 200 day moving average price of $95.62. Encompass Health Co. has a 12-month low of $73.02 and a 12-month high of $104.55. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. The stock has a market cap of $10.17 billion, a P/E ratio of 22.62, a PEG ratio of 1.18 and a beta of 0.90.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. Sell-side analysts anticipate that Encompass Health Co. will post 4.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EHC. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday. Royal Bank of Canada reiterated an “outperform” rating and issued a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. Truist Financial restated a “buy” rating and set a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. KeyCorp boosted their price objective on Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Finally, Barclays raised their target price on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $107.67.

Insider Activity at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.